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Abstract
Background—Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are on the 
rise worldwide but are not well described in pediatric populations. This study characterizes the 
clinical, phenotypic and genotypic characteristics of CRE infections at a free-standing US 
children's hospital.
Methods—CRE were defined as any clinical Enterobacteriaceae isolate non-susceptible to either 
imipenem or meropenem and resistant to ceftriaxone, cefotaxime and ceftazidime determined by 
routine antimicrobial susceptibility testing. The modified Hodge test was performed to screen for 
the production of carbapenemase. Clinical data were reviewed, and molecular characterization of 
phylogenetic and resistance-associated traits was performed.
Results—CRE isolates were recovered from sterile and non-sterile sites in 10 patients, 6 weeks 
to 24 years of age, between 2011 and 2013. Comorbidities included hematologic, genetic and 
urologic abnormalities. Two patients had traveled abroad (India, Lebanon) before CRE recovery. 
Carbapenemase determinants were detected in 5 cases, including KPC-3 in 2 Klebsiella 
pneumoniae (ST258 and ST18) and 1 Escherichia coli (ST131), and NDM-1 in 1 K. pneumoniae 
(ST37) and 1 E. coli (ST101) isolate. Additional resistance determinants were detected, including 
CTX-M-15, SHV-11, TEM-1, CMY-2, CMY-4 and CMY-42. Four patients died, including 2 of 3 
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patients with CRE bacteremia. There was no evidence of epidemiologic or molecular relatedness 
between any 2 cases.
Conclusions—This report documents the appearance of highly resistant Gram-negative 
pathogens in a vulnerable patient population at a pediatric tertiary referral center in a major US 
metropolitan area. Detailed understanding of the distribution and spread of CRE is essential for the 
timely detection and containment of these perilous pathogens.
Keywords
carbapenemase; Klebsiella pneumoniae carbapenemase; New Delhi metallo-beta-lactamase; 
multidrug resistance; Gram-negative rods; Los Angeles
Infections due to carbapenem-resistant Enterobacteriaceae (CRE) are on the rise 
worldwide.1 In the United States, spread of these highly resistant bacteria has been 
associated with sporadic occur-rence in pediatric patients in whom few, if any, approved and 
effective therapeutic options exist.2–5 Carbapenem resistance results from a variety of 
molecular mechanisms, either singly or in combination, including carriage of plasmid-borne 
or chromosomal genes encoding serine carbapenemase or metallo-β-lactamase enzymes; 
expression of efflux pumps or acquisition of an outer membrane porin mutation in 
combination with overproduction of Ambler class A (extended-spectrum beta-lactamase-
type) or class C (AmpC-type) cephalosporinases.6 A potential exists for widespread 
transmission of plasmid-borne carbapenem resistance genes in healthcare and community 
settings.
Risk factors, resistance characteristics and clinical outcomes of CRE infections in pediatric 
patients are not well described. Herein, we present the clinical and molecular details of the 
largest case series to date in a free-standing pediatric hospital in the United States, including 
5 cases of carbapenemase-producing Enterobacteriaceae seen between 2011 and 2013 at the 
Children's Hospital Los Angeles (CHLA).
MATERIALS AND METHODS
Patients and Definition of CRE
CHLA is a 347-bed, free-standing pediatric tertiary care center located in Los Angeles, 
California. Although no adult care facilities are located on this campus, CHLA does serve a 
subset of patients over 18 years of age with pediatric issues who have not yet graduated to 
an adult facility. CHLA does not have a routine screening program for patients with history 
or travel to a CRE endemic region. There have been no identified CRE outbreaks at this 
center. In 2011, we began collecting CRE isolates, defined as any Enterobacteriaceae isolate 
that was non-susceptible to meropenem or imipenem (minimum inhibitory concentration 
(MIC) ≥ 2 μg/mL) and resistant to ceftriaxone (MIC ≥ 4 μg/mL), cefotaxime (MIC ≥ 4 
μg/mL) and ceftazidime (MIC ≥ 16 μg/mL), according to contemporary Clinical and 
Laboratory Standards Institute guidelines (CLSI M100-S23). All isolates were screened for 
the production of carbapenemase by the modified Hodge test (MHT). Then, to detect any 
additional CRE retrospectively, we used the breakpoint criteria to query the microbiology 
laboratory database, which captures antimicrobial susceptibility testing results at our center 
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dating back to 2005. For all CRE cases, clinical data, including medication history and 
details of the hospital course, were extracted from the medical record. The CHLA 
Institutional Review Board approved this study.
Antimicrobial Susceptibility Testing
Specimen processing, bacterial species identification and antimicrobial susceptibility testing 
were performed by the CHLA Clinical Microbiology Laboratory according to contemporary 
Clinical and Laboratory Standards Institute standards (M100-S23). MIC values were 
determined using the Gram-negative susceptibility panel of the Vitek II platform 
(bioMérieux, Durham, NC), Etest (bioMérieux) and/or the Trek Sensititre broth 
microdilution panel for Gram-negative bacteria (Trek Diagnostic Systems, Cleveland, OH). 
To characterize susceptibility to colistin and tigecycline, we used the European Committee 
on Antimicrobial Susceptibility Testing breakpoint criteria of ≤2 μg/mL and ≤1 μg/mL, 
respectively.
Resistance Genotyping
Genotypic analysis, including polymerase chain reaction (PCR) screening for and 
sequencing of genes encoding plasmid-encoded enzymes of the carbapenemase (blaKPC, 
blaNDM, blaIMP, blaVIM, blaOXA-48), AmpC (blaCMY) and extended-spectrum beta-
lactamase (blaCTX-M and blaSHV) types, as well as characterization of the blaKPC-associated 
Tn4401 platform, was performed at the Seattle Children's Research Institute. Briefly, PCR 
reactions were carried out in a total volume of 20 μL reaction mix containing bacterial lysis 
DNA template, JumpStart Taq polymerase Ready Mix (Sigma-Aldrich Inc., St. Louis, MO) 
and primers as listed in Table, Supplemental Digital Content 1, http://links.lww.com/INF/
B971. PCR cycling conditions have been optimized at different annealing temperatures 
(Tann) for different primer sets (Table, Supplemental Digital Content 1, http://
links.lww.com/INF/B971). PCR reactions were carried out using a C1000 Thermal Cycler 
(Bio-Rad, Hercules, CA) under the following conditions: initial denaturation (94°C for 2 
minutes), followed by 30 cycles of denaturation (94°C for 30 seconds), annealing (at 
specified Tann per Table, Supplemental Digital Content 1, http://links.lww.com/INF/B971, 
for 15 seconds) and extension (72°C for 1 minute). PCR-based replicon typing was 
performed for IncF-related plasmid backbones using the method described by Villa and 
colleagues,7 and alleles were assigned using the international plasmid multilocus sequence 
typing (MLST) database (http://pubmlst.org/plasmid/).
Molecular Epidemiology
MLST was performed at Seattle Children's Research Institute for Escherichia coli and 
Klebsiella pneumoniae isolates as previously described.8,9 Sequence type (ST) assignments 
were obtained using the Achtman E. coli MLST database (http://mlst.warwick.ac.uk/mlst) 
and the Institut Pasteur K. pneumoniae MLST database (http://www.pasteur.fr/recherche/
genopole/PF8/mlst/), as appropriate. Then, genetic relatedness was evaluated for all isolates 
using standard pulsed-field gel electrophoresis (PFGE) by XbaI digestion.10
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Statistical comparison was performed using STATA 10.0 (StataCorp LP, College Station, 
TX). Wilcoxon-rank sum test was used to compare the number of antibiotic days between 
groups. A 2-sided P value <0.05 was considered statistically significant.
RESULTS
Clinical Characteristics
Eleven CRE isolates were recovered from 10 patients between April 2011 and May 2013. 
All patients except 1 (patient 8) had underlying medical conditions (Table 1). Eight patients 
had indwelling devices, including central lines (n = 8), endotracheal tubes (n = 3) or surgical 
drains (n = 2); the remaining 2 patients underwent intermittent urinary catheterization 
multiple times daily. International travel in the year preceding CRE recovery was 
documented in 2 patients. Eight patients had a documented hospitalization or Emergency 
Department visit at an outside adult hospital in the year prior to CRE isolation. Patients 
received a median of 28 antimicrobial days, including 20.5 days on Gram-negative-directed 
antimicrobials, during the 6 months prior to CRE isolation. Antimicrobial exposure was 
greater in patients with carbapenemase-producing CRE than in those with carbapenemase-
negative CRE, with regard to both Gram-negative-directed antimicrobials (median, 53 vs. 14 
days, P = 0.028) and carbapenem agents (median, 14 vs. 0 days, P = 0.007).
Treatment regimens and duration varied for each of the 7 episodes of CRE infection in 6 
patients (Table 1). In 4 patients, the CRE isolate was not considered to be a pathogen; thus, 
antimicrobial treatment was not started. Six patients were hospitalized for a mean of 39.3 
days (range: 5–74 days). Four patients died during the hospitalization in which CRE was 
recovered, including 2 of 3 (66.7%) with CRE bacteremia.
Antimicrobial Susceptibility Testing
Susceptibility to typical and alternative non-beta-lactam agents varied between organisms 
(Table 1), although all 11 isolates appeared susceptible to colistin and tigecycline.
Carbapenemase and Cephalosporinase Resistance Genotypes
Carbapenemase genes were identified in 5 isolates. Three isolates from 3 patients encoded 
Ambler class A KPC-3 carbapenemases, including 2 K. pneumoniae and 1 E. coli. Two of 
the blaKPC-3 genes (1 each in K. pneumoniae and E. coli) appeared in the genetic context of 
the Tn4401b transposon isotype with no bla promoter deletion, while the remaining 
blaKPC-3 appeared in the Tn4401d isotype, featuring a 68-bp deletion. Three isolates from 2 
patients carried Ambler class B NDM-1 carbapenemase, including an E. coli in a patient 
who had received medical care in India, and a K. pneumoniae that was isolated initially from 
urine and then from blood in a patient with no known travel history. All E. coli and all but 1 
K. pneumoniae isolates also encoded extended-spectrum cephalosporinase enzymes from 
Ambler classes A (CTX-M) and C (CMY; Table, Supplemental Digital Content 1, http://
links.lww.com/INF/B971).
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MLST and PFGE were used to characterize genetic relatedness among the 11 CRE isolates 
(Fig. 1). MLST profiles and PFGE fingerprints of the 2 isolates from patient 3 were 
indistinguishable, as expected. There was no evidence of strain relatedness between any 2 
patients.
Case Summaries
The 5 patients with carbapenemase-producing isolates are described here.
Case 1—A 20-year-old male who suffered an abdominal gunshot wound at age 16 years, 
resulting in multiple bowel resections, complained of abdominal pain at a routine 
gastroenterology clinic visit but was otherwise in stable condition. Gastrostomy tube 
secretions were cultured and grew K. pneumoniae resistant to carbapenems. The culture was 
considered to represent colonization rather than infection, and the patient was not admitted 
for treatment.
In the 12 months prior to CRE recovery, he had received multiple courses of antimicrobials 
for central line-associated and abdominal wound infections. Of note, 9 months prior to CRE 
recovery, he had central line-associated sepsis with highly susceptible K. pneumoniae 
(resistant only to ampicillin) that was treated with piperacillin–tazobactam for 14 days. Six 
months prior to CRE recovery, he was treated with 17 days of meropenem for a wound 
infection due to extended-spectrum cephalosporin-resistant K. pneumoniae. The patient did 
have a Broviac central line and gastrostomy tube in place at the time of CRE recovery. He 
had visited emergency departments in adult hospitals but had no admissions to hospitals 
with known CRE outbreaks. He had not traveled outside of the United States.
Case 2—A 7-month-old infant with hemophagocytic lymphocytosis diagnosed at 5 months 
of age was transferred to CHLA from an outside hospital for bone marrow transplantation 
evaluation. She had traveled to Lebanon with family prior to her diagnosis. She had received 
etoposide and high-dose steroids. Due to high fever on admission, she was started on 
meropenem. Fever initially resolved but recurred on meropenem, accompanied by emesis 
and diarrhea; stool tested positive for toxigenic Clostridium difficile, and oral vancomycin 
therapy was initiated. Blood culture drawn on hospitalization day (HD) 17 grew K. 
pneumoniae; amikacin was added. Based on a positive MHT and further susceptibility 
testing, colistin was also added. The Broviac line was removed on HD 23, but blood cultures 
remained persistently positive for K. pneumoniae on HD 23, 24, 26 and 27. Ertapenem was 
added on HD 27.11 After the patient developed pneumatosis, Allow Natural Death orders 
were put in place, on HD 27; no further blood cultures were obtained. The patient died on 
HD 32.
Case 3—A 3-year-old male with gangliosidosis and tracheostomy/ ventilator dependence, 
who had been previously treated at another Los Angeles hospital, was admitted to CHLA for 
his 5th cardiopulmonary arrest, ultimately attributed to respiratory infection with 
Staphylococcus aureus and Pseudomonas aeruginosa. He remained hospitalized for 
management of diabetes insipidus. Following multiple daily urinalysis samples with positive 
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leukocyte esterase results, a urine specimen obtained on HD 31 grew >100,000 CFU/ mL of 
P. aeruginosa and 50–100,000 CFU/mL carbapenem-resistant K. pneumoniae (CRKP). 
Repeat urine culture on HD 32 showed pure growth of >100,000 CFU/mL CRKP. He 
received a 14-day course of ciprofloxacin via gastrostomy tube; follow-up urine culture was 
negative. On HD 51, he developed fever, tachycardia and increased work of breathing. 
Blood culture from the peripherally inserted central catheter (PICC) grew K. pneumoniae 
with MICs of 4, 2 and ≤1 for meropenem, doripenem and imipenem, respectively. He was 
thus started on imipenem and colistin (MIC ≤ 0.25). Blood cultures remained positive until 
the PICC was pulled on HD 56. He received 21 additional days of antimicrobial therapy.
Case 4—A 23-year-old female with Blue Rubber Bleb Nevus syndrome, paraplegia, and 
neurogenic bowel and bladder requiring intermittent catheterization who received weekly 
blood transfusions at CHLA presented to a scheduled appointment with headache and 
hypertension. She was noted to have amber-colored urine with a foul smell. The urine 
culture grew carbapenem-resistant E. coli. She completed a 10-day course of nitrofurantoin. 
However, symptoms recurred 15 days later and a repeat urine culture was positive for the 
same organism. She completed a second 10-day course of nitrofurantoin with symptomatic 
improvement.
Although case 4 was of adult age, the patient continued to receive her outpatient care by 
pediatric specialists at our facility. She had 1 inpatient admission to an outside community 
hospital during the 6 months prior to CRE isolation.
Case 5—A 2-year-old girl with myelodysplastic syndrome remarkable for abnormal bone 
marrow cytogenetics (monosomy 7 and trisomy 8) and recurrent fever was transferred to 
CHLA from India for bone marrow transplantation evaluation 7 months prior to CRE 
recovery. Two months prior to CRE isolation, the patient was admitted with fever, 
neutropenia, abdominal distention and bloody diarrhea. Blood culture obtained on HD 13 
grew K. pneumoniae resistant only to ampicillin; she was treated with cefotaxime. When 
blood cultures drawn on HD 19 and 20 grew K. pneumoniae and E. coli resistant to third-
generation cephalosporins but susceptible to meropenem (MIC 0.094 and 0.023, 
respectively) and ampicillin-resistant Enterococcus faecium, therapy was switched to 
meropenem and vancomycin and given for 14 days. The PICC was removed on HD 20, and 
follow-up blood cultures were negative. A new PICC was placed on HD 32. On HD 45, she 
developed sepsis due to K. pneumoniae resistant to third-generation cephalosporins but 
again susceptible to meropenem (MIC 0.064). She was started on meropenem, with negative 
follow-up cultures. The central line was not removed.
On HD 75, on treatment day 30 of meropenem, she developed bacteremia with carbapenem-
resistant E. coli. Meropenem was discontinued and colistin, amikacin and imipenem were 
added on HD 76, 79 and 80, respectively. Liposomal amphotericin was started on HD 76. 
On HD 80, a new black lesion was found on the hard palate. Computed tomography scan 
showed extensive bilateral maxillary and ethmoid sinusitis. The lesion was biopsied 
immediately and grew Aspergillus flavus. Voriconazole was added to liposomal 
amphotericin. Allow Natural Death orders were instituted. The patient died on HD 89.
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This is the largest case series of pediatric CRE at a free-standing children's hospital in the 
United States. KPC-positive K. pneumoniae were first reported in adult patients in 2002 in 
New York state. They spread rapidly throughout the Northeastern United States,12 and by 
2008, were prevalent in the Midwest as well.13,14 The Western United States remained 
largely unaffected until fall 2009, when the Centers for Disease Control and Prevention 
(CDC) contacted the Los Angeles County Department of Public Health (LACDPH) 
regarding detection of identical CRKP in adult patients at several local hospitals. LACDPH 
declared CRKP a laboratory-reportable disease in June 2010, with 814 cases being reported 
in the next 12 months.15 As of February 2014, KPC had been detected in at least 47 states 
(www.cdc.gov/hai/organisms/cre/TrackingCRE.html), with some 70% of KPC-producing K. 
pneumoniae received by the CDC belonging to a single strain, K. pneumoniae ST258.16 The 
KPC-3-positive K. pneumoniae in our pediatric institution were detected in April 2011 
(ST18) and February 2012 (ST258), at least 1 year after the initial detection of CRKP in Los 
Angeles County; the distinctive Tn4401 isotype profiles associated with blaKPC in these 2 
isolates suggested carriage of distinctive plasmids.
KPC has been detected in other Enterobacteriaceae species as well, including Klebsiella 
oxytoca and Enterobacter spp.17–19 More concerning, however, has been the detection of 
KPC in the globally disseminated and highly virulent, multidrug-resistant E. coli ST131 
clone.20 Kim and colleagues described the recovery in Pittsburgh of 7 KPC-2 and KPC-3-
positive E. coli ST131 from September 2008 to February 2011, including 4 with identical 
plasmid restriction patterns, indicating clonal spread.21 The KPC-3-positive E. coli ST131 in 
our study (case 4) was detected in November 2011, but the extent of its relatedness to strains 
from the earlier East Coast cluster remains unclear. Likewise, though this blaKPC-3 was 
associated with the Tn4401b isotype, we are unable to comment without further study on the 
possibility of plasmid sharing between this E. coli and the K. pneumoniae isolate (case 1) 
exhibiting this molecular profile.
In 2010, infections due to E. coli and K. pneumoniae carrying the New Delhi Metallo-beta-
lactamase (NDM) carbapenemase were first reported in patients returning to Western 
Europe from medical tourism travels in India and Pakistan.22 NDM subsequently spread 
throughout Europe, driven in large part by population mobility, including recreational and 
medical travel.23 In June 2010, the CDC reported the first cases of NDM-positive 
Enterobacteriaceae in the United States,24 with the first of these having been recovered in 
April 2009. NDM-producing K. pneumoniae was first recovered in California in December 
2009, with 3 additional cases recovered from September 2010 to March 2011, including 1 
pediatric patient in Los Angeles County2; all 4 cases occurred in patients that had been 
hospitalized in India or Pakistan.25 Carriage of NDM-1 plasmids in the E. coli ST101 strain 
background has been well documented in isolates from India,26,27 consistent with our 
patient's history of birth and medical care in India. However, while NDM-1 plasmids have 
also been reported in K. pneumoniae ST37 isolates from India and the UK,28 our patient 
with NDM-positive K. pneumoniae had no documented history of international travel. 
Detection of NDM positivity in a strain recovered from a patient without known history of 
travel abroad should raise concern for the possibility of person-to-person spread of 
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established NDM-associated plasmids or clones in the community or within the healthcare 
network.
Carbapenemase-positive Enterobacter spp. have been described in North America,18 but no 
plasmid-borne carbapenemases (or cephalosporinases) were detected in the Enterobacter 
isolates in this study. The positive MHT results in these isolates suggest the production of 
beta-lactam-hydrolyzing enzymes, such as de-repressed chromosomal AmpC determinants 
or constitutively expressed plasmid-borne enzymes that were not captured by our panel. 
Production of such enzymes in combination with an outer membrane porin deficiency can 
produce a clinically relevant phenotype of carbapenem resistance29 as well as a false-
positive MHT result.30
We included 1 adult age patient (case 4) who received ongoing care at our pediatric facility. 
Care of patients over 18 years of age is not unusual at an academic referral center, as care 
has improved for diseases that were once considered strictly pediatric conditions. These 
patients may have the additional risk of receiving care in adult facilities where CRE are 
more prevalent.
CRE infection has been associated with high mortality rates in adults.31–33 The Emerging 
Infections Network recently published a case series describing the difficulties in 
management of 85 source patients with CRE reported from across the United States.34 CRE 
was the direct cause or exacerbated conditions leading to death in half of our 6 patients with 
CRE infection. The 3 fatal cases represented the most vulnerable segments of the pediatric 
population, including neonates and those with hematologic malignancies, who require 
complex care and routinely receive empiric antibiotic courses. Prolonged and repeated 
broad-spectrum antibiotic exposure is detrimental to the richly diverse intestinal flora that 
provide colonization resistance against overgrowth of typically minor constituents of the 
flora such as Enterobacteriaceae.35 Although the treatment of CRE infection is confounded 
by the fact that patients who tend to receive broad-spectrum antibiotics are also those at 
greatest risk of complications from infection (and at risk of dose-limiting toxicity from 
combination antibiotics), the principles and practices of Antimicrobial Stewardship36 are 
critical to preserve the dwindling therapeutic options that remain for treatment of these 
highly resistant pathogens.
Even in a metropolitan area with high-CRE prevalence, pediatric infection with these 
perilous pathogens remains rare. The cases we describe in this report appear to represent 
sporadic cases with no molecular or epidemiologic links to one another. Although 2 cases of 
CRE had clear history of international travel and molecular features associated with 
international clones, 1 case of NDM-positive K. pneumoniae infection did not, raising the 
alarming possibility of community or healthcare network spread of the associated global 
clone. LACDPH surveillance has identified CRKP circulating throughout the healthcare 
community as a whole and especially within long-term acute care hospitals.15 The spread of 
CRE infections into pediatric populations highlights the need for active partnerships 
between healthcare facilities and their local public health jurisdiction, which may lead to 
better designed interventions to interrupt CRE transmission within and between health-care 
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facilities. It also magnifies the need for robust Antimicrobial Stewardship programs to 
reduce vulnerability to colonization and infection with these organisms.
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PFGE fingerprints of 11 carbapenem-resistant Enterobacteriaceae. Panel A: K. pneumoniae 
cases #3 (1st and 2nd episodes), #1 and #2. Panel B: E. coli cases #7, #6, #5 and #4. Panel 
C: E. cloacae cases #9, #10 and #8.
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